{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:52:26Z","timestamp":1781823146306,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA247815"],"award-info":[{"award-number":["T32CA247815"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01546-3","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:25:50Z","timestamp":1781774750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5765-8549","authenticated-orcid":false,"given":"John","family":"Sharp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3804-5370","authenticated-orcid":false,"given":"Subodh","family":"Bhatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-9389","authenticated-orcid":false,"given":"Jennifer J.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Elghawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2804-0584","authenticated-orcid":false,"given":"Daniel","family":"Reef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andinet","family":"Teferra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7603-6454","authenticated-orcid":false,"given":"Timothy J.","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5144-3467","authenticated-orcid":false,"given":"Supriya","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-3157","authenticated-orcid":false,"given":"Natalie S.","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-5271","authenticated-orcid":false,"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"1546_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00340-z","volume":"10","author":"CL Batlevi","year":"2020","unstructured":"Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10:74.","journal-title":"Blood Cancer J"},{"key":"1546_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-021-01113-2","volume":"14","author":"W Hanel","year":"2021","unstructured":"Hanel W, Epperla N. Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies. J Hematol Oncol. 2021;14:104.","journal-title":"J Hematol Oncol"},{"key":"1546_CR3","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1182\/bloodadvances.2025019115","volume":"10","author":"J Sharp","year":"2026","unstructured":"Sharp J, Strati P, Bhatta S, Huang JJ, Thomas C, Elghawy O, et al. Real-world outcomes and toxicities of CAR-T in relapsed\/refractory follicular lymphoma: a multicenter cohort study. Blood Adv. 2026;10:3757\u201368.","journal-title":"Blood Adv"},{"key":"1546_CR4","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","volume":"11","author":"KM Linton","year":"2024","unstructured":"Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024;11:e593\u2013e605.","journal-title":"Lancet Haematol"},{"key":"1546_CR5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23:1055\u201365.","journal-title":"Lancet Oncol"},{"key":"1546_CR6","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National Lymphocare Study. J Clin Oncol. 2015;33:2516\u201322.","journal-title":"J Clin Oncol"},{"key":"1546_CR7","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1182\/bloodadvances.2024015719","volume":"9","author":"E Shumilov","year":"2025","unstructured":"Shumilov E, Scholz JK, Seib M, Mazzeo P, Wurm-Kuczera R, Vucinic V, et al. Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma. Blood Adv. 2025;9:3955\u201366.","journal-title":"Blood Adv"},{"key":"1546_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood.2021011994","volume":"141","author":"L Falchi","year":"2023","unstructured":"Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023;141:467\u201380.","journal-title":"Blood"},{"key":"1546_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/path.6294","volume":"263","author":"F Fend","year":"2024","unstructured":"Fend F, Quintanilla-Martinez L. Clonal evolution and relapse in early-stage follicular lymphoma - a tree with many branches(\u2020). J Pathol. 2024;263:271\u20134.","journal-title":"J Pathol"},{"key":"1546_CR10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1182\/blood.2023020999","volume":"143","author":"AJ Radtke","year":"2024","unstructured":"Radtke AJ, Roschewski M. The follicular lymphoma tumor microenvironment at single-cell and spatial resolution. Blood. 2024;143:1069\u201379.","journal-title":"Blood"},{"key":"1546_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3389\/fonc.2018.00219","volume":"8","author":"F Stenner","year":"2018","unstructured":"Stenner F, Renner C. Cancer immunotherapy and the immune response in follicular lymphoma. Front Oncol. 2018;8:219.","journal-title":"Front Oncol"},{"key":"1546_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(25)02360-8","volume":"407","author":"L Falchi","year":"2026","unstructured":"Falchi L, Nijland M, Huang H, Linton KM, Seymour JF, Tao R, et al. Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. Lancet. 2026;407:161\u201373.","journal-title":"Lancet"},{"key":"1546_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01439-x","volume":"16","author":"LCK Ng","year":"2025","unstructured":"Ng LCK, Lee XH, Tan YC, Wong KL, Chow JCY, Ling VWT, et al. Systematic review and meta-analysis: CAR-T vs bispecific antibody as third or later-line therapy for follicular lymphoma. Blood Cancer J. 2025;16:17.","journal-title":"Blood Cancer J"},{"key":"1546_CR14","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1016\/S2352-3026(25)00318-7","volume":"13","author":"M Sorin","year":"2026","unstructured":"Sorin M, Okde R, Goulet M, Ghaleb L, Pang R, Prosty C, et al. Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis. Lancet Haematol. 2026;13:e86\u2013e97.","journal-title":"Lancet Haematol"},{"key":"1546_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1053\/j.seminoncol.2024.02.001","volume":"51","author":"MR Bishop","year":"2024","unstructured":"Bishop MR, Kay GE. CAR T-cell therapy: a collaboration between authorized treatment centers and community oncologists. Semin Oncol. 2024;51:87\u201394.","journal-title":"Semin Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01546-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01546-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01546-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:02:44Z","timestamp":1781820164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01546-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1546"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01546-3","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JJH: Research funding (to the institution): BMS; Honoraria: Eisai, Inc.; Consultancy: AbbVie. CT: Consultancy: Acrotech, Electra Therapeutics. DR: Stock ownership: Regeneron Pharmaceuticals, Intellia Therapeutics, Beam Therapeutics, and Summit Therapeutics. TJV: Advisory Board: Genmab, AbbVie, ADC Therapeutic. Consultancy: Novartis, Recordati, Genmab. Research Funding: Kite, Incyte, Morphosys, Genmab, AbbVie, Recordati. SG: Research funding (to the institution): Imugene Ltd, Pierre Fabre, Kite Pharma. Advisory board: BMS, ADC Therapeutics. NSG: Consultant for: BMS, Regeneron, ADC Therapeutics, Novartis, Incyte, Genentech. Research funding: Cabaletta, Regeneron, Poseida. NE: Research funding (to the institution): BeOne, Lilly, Ipsen, ADC Therapeutics, Incyte, CRISPR Therapeutics; Ad boards for AbbVie, BMS, Merck, Ipsen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Institutional Review Board (IRB) of participating institutions. The study conforms to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A waiver of consent was obtained from local IRBs. The waivers were obtained because of the retrospective nature of the study with minimal risk to the subjects and that many of the patients either passed away or had lost to follow-up since their treatment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent statement"}}],"article-number":"96"}}